Suven Life Sciences secures Product Patents in Mexico and New Zealand

Sanjay Krishna | Myequity news | Date : 07-08-2018 17:55:00 IST

Suven Life Sciences Ltd (Suven) today announced that the grant of one (1) product patent from Mexico (354852) and one (1) product patent from New Zealand (734400) corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2030 and 2036 respectively.

The claims of the patents granted includes the class of selective H3 and 5-HT4 compounds respectively and being developed as therapeutic agents for neurodegenerative disorders such as for the disease like Alzheimer’s which comes under treatment of cognitive impairment associated with neurodegenerative disorders, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

About Suven Life Sciences :

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010, Phase 1 commenced SUVN-911 and Phase 1 ready SUVN-I6107.In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.


More from Myequity